What is Appili Therapeutics Inc (APLIF) stock price today?

Appili Therapeutics Inc (APLIF) is currently trading at $0.01, up 0% today.

What is APLIF P/E ratio?

Appili Therapeutics Inc's P/E ratio is -0.44. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is APLIF return on equity (ROE)?

Appili Therapeutics Inc's return on equity (ROE) is 26.47%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Appili Therapeutics Inc's market cap?

Appili Therapeutics Inc has a market capitalization of $1.46M.

OTC · Biotechnology

Appili Therapeutics Inc (APLIF) Stock

$0.01 +0.00% OTC: APLIF Healthcare

Appili Therapeutics, Inc. operates as a biopharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease.

Valuation

Metric	Value
Price	$0.01
Market Cap	$1.46M
P/E Ratio	-0.44
P/B Ratio	-0.11
P/S Ratio	7.61
EPS (TTM)	$-0.03
52-Week High	$0.03
52-Week Low	$0.01
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	26.47%
ROA	-214.47%
ROCE	33.15%
Gross Margin	96.90%
Operating Margin	—
Net Margin	—
Debt/Equity	-0.75
Current Ratio	0.11

Annual Financials (USD)

Metric	2022	2023	2024	2025	2026
Revenue	$1.0M	$0	$1.0M	$0	$0
Operating Profit	$-24.0M	$-8.0M	$-2.0M	$0	$-7.0M
Net Profit	$-25.0M	$-9.0M	$-4.0M	$-3.0M	$-4.0M
EPS	$-0.38	$-0.08	$-0.03	$-0.02	$-0.03
Op Margin	-1698.1%	-2326.9%	-261.4%	-190.0%	-2675.7%

Balance Sheet (USD)

Metric	2022	2023	2024	2025	2026
Total Assets	$18.0M	$8.0M	$1.0M	$3.0M	$2.0M
Total Liabilities	$6.0M	$12.0M	$12.0M	$16.0M	$19.0M
Cash	$11.0M	$7.0M	$0	$1.0M	$0
Borrowings	$1.0M	$5.0M	$8.0M	$12.0M	$13.0M

Latest News

Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program GlobeNewswire · Jul 3, 2026 Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results GlobeNewswire · Jun 26, 2026

Cash Flow (USD)

Metric	2022	2023	2024	2025	2026
Operating Cash Flow	$-11.0M	$-19.0M	$-2.0M	$1.0M	$-1.0M
Investing Cash Flow	$0	$5.0M	$0	$0	$0
Financing Cash Flow	$8.0M	$0	$0	$0	$0
Net Cash Flow	$1.0M	$-4.0M	$-2.0M	$1.0M	$-1.0M
Free Cash Flow	$-11.0M	$-19.0M	$-2.0M	$1.0M	$-1.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.01
EV / EBITDA	-2.99
FCF Yield	-68.68%
Quick Ratio	0.11
Interest Coverage	-4.49
Return 1Y	—
Return 3Y	—
Return 5Y	—

Ownership

Insiders Held0.06%

Institutions Held10.85%

Institutions Float Held10.85%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAGHAmerica Great Health	$0.00	—	1.00	$2.12M	0.00%
ADXSAyala Pharmaceuticals, Inc.	$0.60	+0.00%	-0.08	$25.71M	0.00%
AGNPFGrey Matters Health Inc.	$0.25	-17.12%	-0.43	$869804	0.00%
HESGHealth Sciences Group, Inc.	$0.00	—	0.00	$1.87M	0.00%
IBOGFUniversal Ibogaine Inc.	$0.02	+6.82%	-0.09	$7.35M	0.00%

About Appili Therapeutics Inc

Appili Therapeutics, Inc. operates as a biopharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. It focuses on building and advancing a diverse portfolio of anti-infective programs such as ATI-1501, ATI-1503, and ATI-1701. The company was founded on May 7, 2015 and is headquartered in Halifax, Canada.

Appili Therapeutics Inc is headquartered in CA.

Appili Therapeutics Inc (APLIF) stock trades at $0.01 with a market capitalization of $1.46M. The stock is valued at a price-to-earnings (P/E) ratio of -0.44, price-to-book of -0.11, price-to-sales of 7.61. Over the past 52 weeks the stock has ranged between $0.01 and $0.03, and currently trades 66.7% below its 52-week high.

On profitability, Appili Therapeutics Inc generates a return on equity (ROE) of 26.47% — well above the market average, a sign of a high-quality business, return on capital employed of 33.15%.

Official website: www.appilitherapeutics.com